We evaluated the impact of high (9.5 log 10 CFU/g) and moderate (5.5 log 10 CFU/g) inocula of methicillinsusceptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) on the activities of nafcillin, linezolid, vancomycin, and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model with simulated endocardial vegetations over 72 h. Human therapeutic dosing regimens for nafcillin, daptomycin, vancomycin, linezolid, and gentamicin were simulated. At a moderate inoculum, nafcillin (MSSA only), vancomycin, and daptomycin demonstrated equivalent and significant (P < 0.01) bactericidal (99.9% kill) activities (decreases of 3.34 ؎ 1.1, 3.28 ؎ 0.4, and 3.34 ؎ 0.8 log 10 CFU/g, respectively). Bactericidal activity was demonstrated at 4 h for nafcillin and daptomycin and at 32 h for vancomycin. Linezolid demonstrated bacteriostatic activity over the course of the study period. At a high inoculum, daptomycin exhibited bactericidal activity against both MSSA and MRSA by 24 h (decrease of 5.51 to 6.31 ؎ 0.10 log 10 CFU/g). Nafcillin (versus MSSA), vancomycin, and linezolid (MSSA and MRSA) did not achieve bactericidal activity throughout the 72-h experiment. The addition of gentamicin increased the rate of 99.9% kill to 8 h for daptomycin (P < 0.01) and 48 h for nafcillin (MSSA only) (P ‫؍‬ 0.01). The addition of gentamicin did not improve the activity of vancomycin or linezolid for either isolate for the 72-h period. Overall, high-inoculum Staphylococcus aureus had a significant impact on the activities of nafcillin and vancomycin. In contrast, daptomycin was affected minimally and linezolid was not affected by inoculum.
Sequestered high-bacterial-density infections such as those observed with endocarditis and osteomyelitis are often difficult to eradicate (4, 53) . Antibiotic failure secondary to problems with antibiotic penetration, inoculum effect, increased protein binding, and stationary-phase organisms make these infections difficult to treat.
Staphylococcus aureus is a common pathogen in sequestered infections, a major cause of infective endocarditis (IE), and has been shown to be an independent predictor of mortality (12, 40) . Vancomycin is currently the drug of choice in treating methicillin-resistant S. aureus (MRSA) infections, which are currently reported to be as high as 51.3% nationwide in intensive care units (14) . Several reports have questioned the efficacy of vancomycin based upon the slow clinical response that often is seen with its use in sequestered infections (34, 39, 51) Additional studies observed that vancomycin is less rapidly bactericidal against S. aureus, especially at higher inoculums (approximately 10 7 CFU) (51) . Also, studies have demonstrated that patients with MRSA infections treated with vancomycin have higher mortality rates than those with methicillin-susceptible S. aureus (MSSA) infections who received nafcillin (55 versus 28%) (27) .
Rapid clearance of a bacterial infection may be necessary to achieve a better prognosis for the patient and may be preferable to use bactericidal agents when treating severe infections such as sepsis, meningitis, and endocarditis (42, 47) . Although limited data exist regarding combination with aminoglycosides, recommendations have been made that when treating S. aureus IE, adding gentamicin for synergy may allow for more rapid sterilization of the cardiac vegetations (56) .
Recently daptomycin, a new lipopeptide antibiotic, was approved for use in complicated skin and soft tissue infections and has demonstrated efficacy against multidrug-resistant gram-positive isolates (7, 9, 57 ; R. D. Arbeit and M. F. DeBruin, Abstr. 41st Intersci. Conf. Antimicrob. Agents and Chemother., abstr. L-1482, 2001 ). This compound currently is in phase 3 clinical trials evaluating its efficacy in patients with endocarditis or bacteremia at a dose of 6 mg/kg every 24 h (q24h) (55) .
We used a previously described in vitro pharmacodynamic model to evaluate several antibiotic regimens using S. aureus at a high inoculum representing the organism density often associated with sequestered infections such as endocarditis and a moderate inoculum incorporated into simulated endocardial vegetations (SEVs) (2, 31) . To date, there has been no direct comparison between the use of nafcillin, daptomycin, linezolid, and vancomycin alone and in combination with gentamicin in the treatment of sequestered high-inoculum infections such as infective endocarditis.
(A portion of this work was presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 14 to 17 September 2003, and at the 7th g/ml. Nafcillin and linezolid were administered to simulate 2 g q4h (peak, 40 g/ml) and 600 mg q12h (peak, 18 g/ml), respectively, with the pump rate set to achieve half-lives of 1 and 5 h, respectively (26) . Gentamicin was administered to simulate a dose of 1.3 mg/kg q12h (approximate peak, 6 g/ml; trough, 0.4 g/ml), and the pump rate was set to achieve a half-life of 3 h.
For combination regimen experiments, the elimination rate was set for the drug with the shortest half-life, the drug with the longer half-life was supplemented (11) . All model experiments were performed in triplicate to ensure reproducibility. In addition, simulations in the absence of antibiotics were performed to ensure adequate growth of the organisms in the model. Pharmacodynamic analysis. Two SEVs were removed from each model, for six simulated vegetations at 0, 4, 8, 24, 32, 48 , and 72 h. The SEVs were homogenized and diluted in cold saline and plated onto TSA plates. The pH was monitored throughout all experiments with daptomycin due to the possible effects on its activity (37) . Plates were incubated at 35°C for 24 h, at which time colony counts were performed. Reductions in log 10 CFU per gram over 72 h were determined by plotting time-kill curves. Bactericidal activity (99.9% kill) was defined as a Ն3-log 10 -CFU/ml reduction in colony count from the initial inoculum. Bacteriostatic activity was defined as a Ͻ3-log 10 -CFU/ml reduction in colony count from the initial inoculum, while inactivity was defined as no observed reductions in initial inoculums. The time to achieve 99.9% kill was determined by nonlinear regression (using a minimum of 4 data points) if r 2 Ն 0.95, or by visual inspection. Enhancement of activity was defined as an increase in kill of Ն2-log 10 CFU/ml by a combination of antimicrobials versus the most active single agent of that combination. Improvement was defined as a 1-to 2-log 10 -CFU/ml increase in kill in comparison to the most active single agent, while combinations that resulted in Ն1-log 10 bacterial growth in comparison to the least active single agent were considered to represent antagonism (1). The terms "improvement" and "enhancement" were used because our simulations used therapeutically obtained serum drug concentration, and this did not permit the mathematical modeling necessary to consider the standard terms "additivity" and "synergy" (3). Indifference was defined as no differences. Reductions in colony counts were determined over a 72-h period and will be compared between regimens.
Pharmacokinetic analysis. Samples for pharmacokinetic analyses were obtained through the injection port at 0.5, 1, 2, 4, 8, 24, 32, 48, 56, and 72 h for verification of target antibiotic concentrations. In addition, antimicrobial concentrations in SEVs were determined and compared to model concentrations to determine percent penetration over time. All samples were stored at Ϫ70°C until ready for analysis. Vancomycin and gentamicin concentrations were determined by fluorescence polarization immunoassay (Abbott Diagnostics TDx). The assay for vancomycin and gentamicin has limits of detection of 2.0 and 1.13 g/ml, respectively, and between-day sample precision levels (percent coefficient of variation [CV%]) of Յ4.8 and Յ3%, respectively. Linezolid concentrations were determined by a previously described validated high-pressure liquid chromatography assay (3) . Linezolid concentrations were determined at the Division of Infectious Diseases at the National Jewish Medical and Research Center (Denver, Colo.) using a validated high-performance liquid chromatography assay that conforms to the guidelines set forth by the College of American Pathologists. The standard curve for linezolid in plasma ranged from 2.06 to 19.51 g/ml. The between-day sample precision CV% was Յ5.3%. Concentrations of daptomycin and nafcillin were determined by microbioassay utilizing Micrococcus luteus ATCC 9341. Blank 1/4-mm disks were spotted with 20 l of the standards or samples. Each standard was tested in triplicate by placing the disk on MuellerHinton agar plates that were preswabbed with a 0.5 McFarland suspension of the test organism. Plates were incubated for 18 to 24 h at 37°C, after which time the zone sizes were measured. Concentrations of 150, 50, 10, and 5 and 8, 4, 2, and 1 g/ml were used as standards for daptomycin and nafcillin, respectively. The nafcillin samples were inoculated onto disks at a 1:10 dilution. The daptomycin and nafcillin bioassay has lower limits of detection of 2.5 and 1 g/ml, respectively, and between-day sample CV%s of Յ11.1 and Յ7.8%, respectively (1). The half-lives and area under the curve (AUC), maximum concentration (C max ), and minimum concentration (C min ) of the antibiotics were determined by the trapezoidal method, utilizing PK Analyst software (version 1.10; MicroMath Scientific Software, Salt Lake City, Utah).
Resistance. Development of resistance was evaluated for each combination and monotherapy model at 24, 48, and 72 h. One hundred-microliter samples from said time points were plated on TSA plates containing four-and eightfold the MIC of the respective antibiotic to assess the development of resistance. Plates were examined for growth after 48 h of incubation at 35°C.
Statistical analysis. Changes in CFU per gram at 24, 48, and 72 h and time to 99.9% kill were compared by two-way analysis of variance with Tukey's post hoc test. A P value of Յ0.05 was considered significant. All statistical analyses were performed with SPSS Statistical Software (release 11.1; SPSS, Inc., Chicago, Ill.).
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RESULTS

Susceptibility testing.
All susceptibility results are reported in Table 1 . At a high inoculum, MICs for both MSSA and MRSA strains increased 32-fold for daptomycin, 4-fold for vancomycin, and 4-fold for nafcillin against the MSSA strain. With respect to the MSSA test strain, the presence of albumin resulted in fourfold MIC increases for nafcillin and vancomycin and a twofold increase for daptomycin. In the presence of a high inoculum and albumin, the daptomycin, vancomycin, and nafcillin MICs increased 32-, 8-, and 128-fold, respectively. MICs of linezolid were unchanged in the presence of physiological concentrations of albumin and/or by increased inoclum.
Pharmacokinetics. Pharmacokinetic parameters (Ϯ standard deviation) for the tested agents are shown in Table 2 . Observed kinetics and peak concentrations were within 8 to 10% of the targeted value. The concentrations in the SEVs were obtained and compared to concentrations in the broth at 24 h. The C max percent drug concentration (micrograms per gram) within the first 24 h in the homogenized SEVs for nafcillin, vancomycin, linezolid, daptomycin, and gentamicin ranged from 22 to 61%.
Pharmacodynamics. Results of 72-h pharmacodynamic models for moderate-and high-inoculum MSSA and MRSA SEVs are shown in Fig. 1 and 2 . Quantitative changes in the bacterial population (change in log CFU per gram over 72 h) with each drug exposure are portrayed in Table 2 . For all model simulations, pH ranged between 6.98 and 7.06 and the temperature was maintained at 37°C throughout the 72-h experiment.
Moderate inoculum. At a moderate inoculum (5 ϫ 10 5 log 10 CFU/g), (Fig. 1A and B) , nafcillin and daptomycin were equally effective against MSSA and MRSA (not nafcillin), as demonstrated by achieving bactericidal activity as early as 4 h, and remained bactericidal throughout the 72-h experiment. The time above the MIC in the presence of albumin, T Ͼ MIC (albumin) , was 100% for nafcillin throughout the study, and the AUC/ MIC (albumin) ratio for daptomycin was 1,511.
Vancomycin demonstrated bactericidal activity at 48 h against both isolates and remained bactericidal to the 72-h endpoint. The achieved AUC/MIC (albumin) ratios were 149 for the MSSA isolate and 298 for the MRSA isolate. Linezolid demonstrated bacteriostatic activity throughout the 72-h study, the AUC/MIC (albumin) ratio was 133. Both vancomycin and linezolid concentrations demonstrated 100% T Ͼ MIC (albumin) .
High inoculum. Changes in bacterial density (log 10 CFU per milliliter) over 72 h are in Table 3 , and the achieved pharmacodynamic parameters are shown in Table 4 . The high-inoculum (albumin) MIC of nafcillin was 16, and therefore the T Ͼ MIC (albumin) for nafcillin was less than 38%. At a high inoculum, nafcillin alone did not demonstrate significant activity throughout the 72-h experiment, however, bactericidal activity was noted by 48 h when gentamicin was used in combination with nafcillin (P ϭ Ͻ 0.01).
Against MSSA and MRSA isolates at a high inoculum (5 ϫ 10 9 log 10 CFU/g) ( Fig. 2A and B) , daptomycin achieved bactericidal activity by 24 h and maintained this for the duration of the experiment (P ϭ Ͻ0.001). Nonlinear regression extrapolated 99.9% kill to occur at 11.8 and 13.2 h (R 2 ϭ Ն0.94) for MSSA and MRSA, respectively. The high-inoculum AUC/ MIC (albumin) ratios for daptomycin against MSSA and MRSA were 94 and 47, respectively. Although not statistically significant, gentamicin increased the rate of daptomycin's bactericidal activity to 8 h for both MSSA and MRSA, thus increasing the time to 99.9% kill by approximately 3.8 to 5.2 h.
Vancomycin achieved bactericidal activity at 72 h, and no differences were noted when gentamicin (simulated doses targeting a peak of 6 g/ml every 12 h) was added to vancomycin. Vancomycin's T Ͼ MIC was 100% for each simulation. At a high inoculum, the achieved AUC/MIC (albumin) ratios were 75 against the MSSA isolate and 149 against the MRSA isolate. This apparent discrepancy was the result of baseline differences in MICs between the two organisms.
Linezolid demonstrated bacteriostatic activity similar to what was observed at the moderate inoculum. Our results illustrate that for linezolid the time above the MIC (T Ͼ MIC) was 100% throughout the experiments. The AUC/MIC ratio for linezolid was 133. Bacteriostatic activity was noted at 24 h and remained bacteriostatic throughout the 72-h experimental period. There was no additional benefit when gentamicin was added to the regimen. Detection of resistance. Resistance was detected in the gentamicin monotherapy model. There was a four-to sixfold increase in MIC at 48, 56, and 72 h against both the MSSA and the MRSA isolates. There was no resistance noted at any time point in the nafcillin, daptomycin, vancomycin, or linezolid models with monotherapy or combination regimens.
DISCUSSION
IE is a sequestered infection that often yields a high bacterial density (10 8 to 10 10 organisms per g of tissue). As these infections progress, rates of metabolism and cell division appear to be reduced and biofilm production can occur, perhaps as a result of nutrient limitations (4). Clinical cure is often achieved, but prolonged administration of relatively high doses of a bactericidal cell wall-active antibacterial agent is generally required for sterilization of the vegetation (44) . Additionally, these types of infections are commonly seen in immunocompromised patients who possess several risk factors for harboring multidrug-resistant organisms (4, 59) .
Over 60 years ago, Eagle described an in vitro phenomenon called the "inoculum effect." This effect has been observed in gram-positive bacteria exposed to ␤-lactam antibiotics and glycopeptides such as vancomycin (52, 53) . This is believed to occur as a result of the cell wall-active agents' mechanism of 
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on June 25, 2017 by guest http://aac.asm.org/ action. For example, vancomycin, penicillin, and other ␤-lactams interact and inhibit synthesis of the cell wall in the bacterial cytoplasmic membrane. This binding results in a series of interactions that lead to inhibition of growth and eventual death of the organism. When there is an overwhelming number of bacteria and lack of nutrients at the core of the infection (and therefore organisms in stationary phase), these agents are unable to reach their target site on a growing cell wall (24) . Controversy exists regarding the true impact of an in vitro inoculum effect in clinical settings; however, several studies have demonstrated this effect in vitro (23, 25, 33, 37, 45, 54) .
Stevens et al. demonstrated that during the stationary phase of bacterial growth, penicillin binding proteins 1 and 4 were undetectable in a high inoculum (10 8 ); therefore, primary target proteins for penicillin were nonexistent (52, 53) .
In our study, nafcillin at high inoculum (9.5 log 10 CFU/g) did not demonstrate any significant reduction in bacterial densities throughout the 72-h study. However, when the study was repeated at a moderate inoculum of 5.5 log 10 CFU/g, nafcillin elicited a rapid decline in bacterial densities as early as 4 h and throughout the entire 72-h experiment.
Nafcillin's efficacy has been pharmacodynamically correlated to T Ͼ MIC, which is the cumulative percentage of time over a 24-h period that the drug concentration exceeds the MIC for the organism (8) . At the moderate inoculum, the T Ͼ MIC (albumin) was 100% throughout the 72-h experiment; however, the T Ͼ MIC (albumin) at a high inoculum was 38%; this (16, 36) .
Vancomycin has been the drug of choice for treating MRSA infections for several decades. This drug has demonstrated efficacy against multidrug-resistant gram-positive bacteria in sequestered infections such as endocarditis and osteomyelitis (39, 51) . There have been several studies which demonstrate vancomycin's kill to be significantly encumbered during stationary phases of bacterial growth, under anaerobic conditions, and at an increased inoculum (29, 37, 38) . In addition, patients with S. aureus IE have demonstrated positive blood cultures after 7 days of therapy with vancomycin and have a slower response and longer duration of bacteremia than patients treated with ␤-lactams (27, 39, 40) . One in vivo study evaluated the efficacy of ␤-lactam antibiotics versus vancomycin in the treatment of S. aureus infections. Investigators observed that ␤-lactam antibiotics were more effective at the 3-and 7-day time points than vancomycin (58) . We demonstrated a delay in killing when a high inoculum (9.5 log 10 CFU/g) was compared to a moderate inoculum (5.5 log 10 CFU/g): 48 versus 72 h for both the MSSA and MRSA organisms.
A number of studies have evaluated the potential use of synergy with gentamicin combined with vancomycin; they demonstrate mixed results. This combination is not considered a more effective option for the treatment of MRSA infections due to the increased risk of nephrotoxicity (as much as four to five times baseline) but has been used frequently due to slow response to monotherapy with vancomycin and lack of suitable alternatives (28, 49, 50) . In our investigation of a high-inoculum sequestered infection, we noted slow bactericidal activity of vancomycin, which was obtained at 72 h and showed no improvement with the addition of gentamicin. Furthermore, we noted an eightfold increase in MICs when vancomycin was tested at a high inoculum in the presence of physiological concentrations of albumin in humans.
The therapeutic efficacy of vancomycin has been pharmacodynamically correlated with both T Ͼ MIC and AUC over 24 h divided by the MIC (AUC/MIC) (20, 38) . We evaluated both parameters at moderate-and high-inoculum MICs in the presence of albumin (41) . The T Ͼ MICs were 100 and 80% for all for simulations with vancomycin against both isolates at moderate and high inocula, respectively. Despite achieving maximal target attainment for this parameter, we observed a significant reduction in overall kill and time to achieve bactericidal activity at high inocula. This may be related to the fact that the AUC/MIC (albumin) ratio was reduced by 50% for both the MSSA and MRSA isolates when vancomycin was evaluated at high inoculum.
There have been mixed results demonstrating an inoculum effect with daptomycin. Although we observed a 16-fold increase in the MIC under a high bacterial inoculum, this only translated to a delay in bactericidal kill activity of about 4 h, by extrapolation of nonlinear regression. However, the overall extent of killing at high inocula was equal to that observed at on June 25, 2017 by guest http://aac.asm.org/ the moderate inoculum. Earlier studies noted that an increase in the bacterial inoculum from 10 3 to 10 6 CFU/ml had little effect on the activity of daptomycin (6) . Another study reported that inoculum size had minimal effect on daptomycin in time-kill studies (19) . In our high-inoculum model, we identified a delay in, but not a significant impact on, the overall activity of daptomycin in the presence of a high bacterial load.
We also observed in our high-inoculum sequestered infection model, that daptomycin demonstrated rapid bactericidal kill of both MSSA and MRSA test strains by 24 h. Several in vitro studies have addressed the effect of combination therapy containing daptomycin; however, a limited number of clinical studies have examined this effect (1, 18) . Most commonly, these studies evaluate the effect of daptomycin in combination against Enterococcus spp. (2). One study demonstrated that daptomycin in combination with an aminoglycoside resulted in synergistic activity at 48 h against glycopeptide-intermediate S. aureus isolates (1). We observed no additional additivity at the 72-h endpoint when gentamicin was added to daptomycin. However, we did demonstrate an increase in the rate of bactericidal activity at 8 h when gentamicin combination therapy was used, while daptomycin alone demonstrated bactericidal activity at 24 h.
Daptomycin efficacy has also been correlated with AUC/ MIC (1, 22, 36) . Our study resulted in an AUC/MIC (albumin) ratio of 1,511 for both MSSA and MRSA at moderate inoculum. This ratio is consistent with previous studies testing the same isolates at a moderate inoculum and falls within the range of AUC/MIC free of 171 to 442 providing maximum kill Linezolid is an oxazolidinone antibiotic that exerts its antibacterial effect by interfering with protein synthesis. In our study, linezolid did not demonstrate an inoculum effect in moderate-or high-bacterial-density experiments. Our data are consistent to observations reported in similar studies.
Recently, there have been published case reports and animal studies that found mixed results in treating S. aureus IE with linezolid (21, 32) . One study reported that vancomycin alone was more effective than either the combination of linezolid and vancomycin or linezolid alone for the treatment of MRSA endocarditis (18) . Additionally, there have been several clinical reports of treatment failures (10, 46, 48) . Our results are consistent with several published in vivo and in vitro studies suggesting that linezolid is bacteriostatic and may not be effective in patients with complicated sequestered infections such as infective endocarditis. Synergy or additivity is rarely demonstrated in combination therapy with linezolid, which was what we observed in our infection model (3) .
Linezolid efficacy have been pharmacodynamically correlated with both T Ͼ MIC and AUC/MIC. In our investigation, linezolid concentrations exceeded the T Ͼ MIC for 100% of the dosing interval and the AUC/MIC parameter was 133, a known ratio to achieve success against staphylococci (5). Although this parameter was maximized, we did not find any significant decrease in bacterial density with linezolid at moderate and high inocula against MSSA and MRSA. This may be related to the fact that linezolid acts on the ribosomes, whereas daptomycin, nafcillin, and vancomycin target the cell wall.
S. aureus is capable of producing biofilm especially at a higher inoculum and stationary phase (37, 52, 53, 59) . Once a biofilm is present, antibiotics may have difficulty penetrating to the site at which the organism resides (4, 59) . However, more recent evidence suggests that it may not be the antibiotic's inability to penetrate but rather inactivity of the antibiotic in the biofilm (4, 13, 35, 59 ). We did not directly investigate the presence of a biofilm in our in vitro model. It is feasible that such production may have been a contributory factor to the lack of efficacy demonstrated by nafcillin and vancomycin at a high inoculum.
Conclusion. Although monotherapy and combination regimens were investigated in our in vitro models, a limitation of this study is the use of single MSSA and MRSA isolates. In addition, we cannot conclude with certainty that our results will hold true with treatment durations longer than 72 h. Twoand 4-week courses of therapy with nafcillin and vancomycin have demonstrated clinical efficacy in patients with IE (16, 17) . The majority of our monotherapy and combination regimens have been consistent with previous clinical studies and other in vitro and animal models (1, 15, 17, 27) . However, our results should be applied to clinical practice with caution. The inoculum appears to influence the activity of nafcillin Ͼ vancomycin Ͼ daptomycin Ͼ linezolid. Nonetheless, confirmation of our results with further clinical studies would be beneficial before these regimens can be adopted for use in the care of patients.
